Search our Database of Scientific Publications and Authors

I’m looking for a

    2021 results match your criteria Allergy and Asthma Proceedings[Journal]

    1 OF 41

    Drug-induced eosinophilia.
    Allergy Asthma Proc 2018 May;39(3):252-256
    Department of Allergy and Immunology, Allegheny Health Network, Pittsburgh, Pennsylvania.
    Background: Drug reactions have been associated with increased blood eosinophil levels.

    Objective: To review clinical characteristics, the diagnosis, and the management of drug-induced eosinophilia.

    Methods: Pertinent articles were selected and reviewed in relation to a case presentation of drug-induced eosinophilia. Read More

    Utilization and timeliness of an inpatient penicillin allergy evaluation.
    Allergy Asthma Proc 2018 May;39(3):245-251
    Division of Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota.
    Background: A history of penicillin allergy is associated with an increased risk of nosocomial infections because patients are exposed to non-beta lactam antibiotics. Ruling out inaccurate penicillin allergy during hospitalization decreases prescription of beta lactam antibiotics. However, the utilization of penicillin allergy testing and timeliness in relation to initiation of antibiotics is not known. Read More

    Prevalence of allergen sensitization detected by patch tests.
    Allergy Asthma Proc 2018 May;39(3):240-244
    Department of Dermatology, Mayo Clinic, Scottsdale, Arizona.
    Background: Existing literature on the prevalence of positive reactions to allergens is largely derived from dermatologists who practice at large academic centers. Data from other providers, including allergists who practice in various other settings, is important to assess a more representative and accurate prevalence of contact allergy.

    Objective: To determine the prevalence of contact allergy among individuals with at least one positive patch test result by comparing data for positive patch test reaction rates of common contact allergens from 3 groups based in different practice settings, 2 of which are academic. Read More

    Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations.
    Allergy Asthma Proc 2018 May;39(3):232-239
    Glenmark Pharmaceuticals Inc, Mahwah, New Jersey.
    Background: GSP301 is a fixed-dose combination (FDC) of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate developed as a single nasal spray (NS).

    Objective: To assess the relative bioavailability of mometasone administered as GSP301 FDC versus two mometasone monotherapy NS formulations.

    Methods: In this single-dose, open-label, crossover study, healthy adults (age range, 18-65 years) were randomized equally to one of six treatment sequences for three 72-hour treatment periods with GSP301 (olopatadine 665 μg-mometasone 50 μg), the mometasone furoate monotherapy component of GSP301 (MF-sponsor, 50 μg), and U. Read More

    Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations.
    Allergy Asthma Proc 2018 May;39(3):224-231
    Glenmark Pharmaceuticals, Inc., Mahwah, New Jersey.
    Background: GSP301 is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate developed as a single nasal spray.

    Objective: To assess the relative bioavailability of olopatadine administered as GSP301 versus two olopatadine monotherapy nasal spray formulations.

    Methods: In this single-dose, open-label, crossover study, healthy adults (18-65 years old) were equally randomized to one of six treatment sequences for three 48-hour treatment periods with GSP301 (olopatadine 665 μg-mometasone 50 μg), the olopatadine monotherapy component of GSP301 (OLO-sponsor; 665 μg) and U. Read More

    Hereditary angioedema from the patient's perspective: A follow-up patient survey.
    Allergy Asthma Proc 2018 May;39(3):212-223
    Department of Medicine, University of California San Diego, La Jolla, California.
    Background: We conducted our first patient survey at the 2013 hereditary angioedema (HAE) patient summit and learned that, despite several novel therapies, the burden of disease was high.

    Objective: To determine, from the patient's perspective, if any improvements in the current state of HAE care occurred over a two-year period between HAE patient summits.

    Methods: A patient survey was conducted at the 2015 Hereditary Angioedema Association conference by using paper surveys that aimed at understanding the current state of HAE care. Read More

    Diagnosis, pathogenesis, and treatment of chronic spontaneous urticaria.
    Allergy Asthma Proc 2018 May;39(3):184-190
    Background: Chronic Spontaneous Urticaria (CSU) is an endogenous disorder that is strongly associated with autoimmunity, particularly with immunoglobulin G (IgG) antibody to the alpha subunit of the IgE receptor seen in 35-40% of patients. Basophils and cutaneous mast cells can be activated and lead to a late-phase-like perivascular infiltration about small venules and hive formation.

    Methods: Review of current literature. Read More

    Evaluating children with suspected allergic reactions to vaccines for infectious diseases.
    Allergy Asthma Proc 2018 May;39(3):177-183
    Clinica Pediatrica, Dipartimento di Medicina e Chirurgia, Università di Parma, Parma, Italy.
    Background: Vaccines often contain potentially allergenic material in addition to pathogen-specific immunogens that may induce allergic reactions. Parents and physicians often suspect that adverse reactions to vaccines are allergic in etiology. The concern that some of the substances contained in vaccines may trigger an anaphylactic reaction may lead to a low vaccination adherence with emergence of infectious disease epidemics. Read More

    Nonprescription medications for respiratory symptoms: Facts and marketing fictions.
    Allergy Asthma Proc 2018 May;39(3):169-176
    Pharmacy and Pediatrics, University of Florida, Gainesville, Florida.
    Background: There are many nonprescription (over-the-counter [OTC]) medications available on pharmacy shelves marketed for relief of respiratory symptoms. The number of such medications has been increasing.

    Objective: This review provides an evidence-based examination of OTC products used for respiratory symptoms. Read More

    Epidemiology of childhood asthma in mainland China (1988-2014): A meta-analysis.
    Allergy Asthma Proc 2018 May;39(3):15-29
    From the Department of Epidemiology, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China.
    Background: After the promotion of the two-child policy in recent years, the population of children in mainland China was bound to have a rapid growth, which would bring great challenges to public health. A number of cross-sectional studies on the epidemic of childhood asthma in mainland China were recently conducted, and varied prevalences were reported. Thus, knowing the epidemiology of childhood asthma in mainland China is of great necessity. Read More

    Correlation between vitamin D serum levels and passive smoking exposure in children with asthma.
    Allergy Asthma Proc 2018 May;39(3):8-14
    Section of Paediatrics, Department of Surgery, Dentistry, Gynaecology and Paediatrics, University of Verona, Verona, Italy.
    Objective: To establish the relationship between vitamin D serum levels, pulmonary function, asthma control, and passive smoking exposure in children with asthma.

    Methods: We studied the relationship between 25-hydroxy cholecalciferol (25[OH]D) concentrations and baseline spirometry and levels of asthma control, and the effect of parental tobacco smoke exposure in 152 white children (84 boys [55.3%]) with a mean age ± standard deviation of 9. Read More

    Perinatal risk factors for asthma in children with allergic rhinitis and grass pollen sensitization.
    Allergy Asthma Proc 2018 May;39(3):1-7
    Department of Neonatology and Pediatric Intensive Care, Children's Hospital, University of Bonn, Bonn, Germany.
    Background: Results of epidemiologic studies have determined several risk factors for asthma in school-age children.

    Objective: To examine whether parental and perinatal risk factors, along with infantile feeding patterns, were associated with asthma in children with grass pollen allergy and allergic rhinitis.

    Methods: We retrospectively analyzed the data of our cohort, which consisted of children with allergic rhinitis. Read More

    Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.
    Allergy Asthma Proc 2018 Mar 20. Epub 2018 Mar 20.
    Background: Bilastine is an H1-antihistamine approved for symptomatic treatment of patients with allergic rhinoconjunctivitis or urticaria. The safety profile of bilastine in clinical trials of allergic rhinoconjunctivitis or urticaria, assessed by type and frequency of adverse events (AE), was similar to that of placebo.

    Objective: As part of the risk management plan for bilastine, the safety profile of bilastine in the elderly was assessed. Read More

    Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States.
    Allergy Asthma Proc 2018 May 7;39(3):201-211. Epub 2018 Mar 7.
    Herbert Wertheim School of Medicine, Florida International University, Miami, Florida.
    Background: Chronic idiopathic urticaria (CIU)/spontaneous urticaria (CSU) is defined by the presence of wheals, angioedema, or both for ≥6 weeks, with or without an identifiable trigger. Real-world health care data among children with CIU/CSU remain scarce.

    Objectives: To describe treatment patterns, health care resource utilization (HRU), and costs in pediatric patients with CIU/CSU (<12 years old) and to compare these with pediatric patients without CIU/CSU. Read More

    Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E.
    Allergy Asthma Proc 2018 Mar;39(2):153-160
    From the Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston. Massachusetts.
    Background: Cytokine interleukin (IL) 31 has emerged as an important component of allergic and inflammatory diseases associated with pruritus, such as atopic dermatitis (AD) and mastocytosis. Mast cells (MC) are stimulated by allergic and nonallergic triggers, and play a critical role in such diseases by secreting histamine and tryptase as well as cytokines and chemokines. IL-33 has been reported to augment MC responses, but its effect on secretion of IL-31 is not known. Read More

    induction of T regulatory cells by a methylated CpG DNA sequence in humans: Potential therapeutic applications in allergic and autoimmune diseases.
    Allergy Asthma Proc 2018 Mar;39(2):143-152
    Division of Rheumatology, Milton S. Hershey Medical Center at Penn State University, Hershey PA.
    Background: Allergic and autoimmune diseases comprise a group of inflammatory disorders caused by aberrant immune responses in which CD25+ Forkhead box P3-positive (FOXP3+) T regulatory (Treg) cells that normally suppress inflammatory events are often poorly functioning. This has stimulated an intensive investigative effort to find ways of increasing Tregs as a method of therapy for these conditions. One such line of investigation includes the study of how ligation of Toll-like receptors (TLRs) by CpG oligonucleotides (ODN) results in an immunostimulatory cascade that leads to induction of T-helper (Th) type 1 and Treg-type immune responses. Read More

    Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial.
    Allergy Asthma Proc 2018 Mar;39(2):110-116
    Atlanta Allergy and Asthma Clinic, Marietta, Georgia.
    Background: The safety of a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) has been established in adults and adolescents with allergic rhinitis but not in children <12 years old.

    Objective: To evaluate the safety and tolerability of an intranasal formulation of AZE and FP in children ages 4-11 years with allergic rhinitis.

    Methods: The study was a randomized, 3-month, parallel-group, open-label design. Read More

    Association between psoriasis and asthma risk: A meta-analysis.
    Allergy Asthma Proc 2018 Mar;39(2):103-109
    Background: Psoriasis has been shown to be related to an increased risk of asthma, although the results remain inconclusive. Therefore, we performed a meta-analysis to determine whether psoriasis increases the risk of asthma.

    Methods: A comprehensive search of medical literature data bases was conducted through May 2017. Read More

    Association of alopecia areata with atopic dermatitis and chronic spontaneous urticaria.
    Allergy Asthma Proc 2018 Mar;39(2):96-102
    From the Leumit Health Services, Tel-Aviv, Israel.
    Background: Epidemiologic studies report that alopecia areata (AA) is related to various atopic and autoimmune diseases. The purpose of this study was to identify clinical characteristics and the prevalence of comorbid conditions in Israeli patients with AA.

    Methods: This retrospective, matched, case-control study was based on data from an electronic patient record data base. Read More

    Association between urticaria and nematode infections.
    Allergy Asthma Proc 2018 Mar;39(2):86-95
    From the School and Division of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University Hospital "G. Martino," Messina, Italy.
    Background: The association between parasites and urticaria was first suggested in the last century. A wide range, 0-75.4%, of the prevalence of parasitic infection has been reported with chronic urticaria (CU). Read More

    Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.
    Allergy Asthma Proc 2018 May 19;39(3):191-200. Epub 2018 Feb 19.
    Bernstein Clinical Research Center, Cincinnati, Ohio.
    Background: Omalizumab was approved for the treatment of chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in the United States in March 2014.

    Objective: This study sought to describe real-world omalizumab use, in the United States, in a large cohort of patients with CIU/CSU.

    Methods: Patients with CIU/CSU (ages ≥12 years) initiated on omalizumab (index date) with ≥12 months of pre- and postindex data were identified in the an insurance claims data base (January 1, 2013, to July 31, 2016). Read More

    Randomized trial to assess the efficacy and safety of beclomethasone dipropionate breath-actuated inhaler in patients with asthma.
    • Authors:
    Allergy Asthma Proc 2018 Jan 9. Epub 2018 Jan 9.
    Background: Breath-actuated inhalers (BAI) eliminate the need for the hand-breath coordination required with standardmetered-dose inhalers (MDI).

    Objective: To evaluate the efficacy and safety of beclomethasone dipropionate (BDP) administered via BAI.

    Methods: This 6-week, phase III, double-blind study included patients aged greater than or equal to 12 years with persistent asthma. Read More

    Evaluating satisfaction of patients with hereditary angioedema with their past and present treatments: Implications for future therapies.
    Allergy Asthma Proc 2018 Jan;39(1):74-80
    Background: Ever-expanding armamentarium of treatments for hereditary angioedema (HAE) are associated with various adverse effects, issues with vascular access, or lack of self-administration.

    Objective: To understand patients' impressions and confidence in their past and present treatments, and identifying adverse events while also directly asking patients to reveal their hope for the future of HAE management and treatments.

    Methods: After institutional review board approval, all subjects with laboratory-confirmed HAE were mailed a survey that they completed and returned to the researchers, and data were collected and entered into a secure online web application for surveys. Read More

    Comparison of the effect of 5-grass pollen sublingual immunotherapy tablets and drops in children with rhinoconjunctivitis.
    Allergy Asthma Proc 2018 Jan;39(1):66-73
    Background: One of the most important aspects of sublingual immunotherapy (SLIT) is the regimen of administration.

    Aim: To find any differences in symptom-medication scores between the two groups of SLIT tablets and drops, given pre-coseasonally (starting 8 weeks before the pollen season) in children with rhinoconjunctivitis allergy to grass pollen. The secondary outcome were the differences in lung function and induction of T-regulatory forkhead box P3 (FOXP3) positive cells. Read More

    Characteristics of beef allergy in schoolchildren in Turkey.
    Allergy Asthma Proc 2018 Jan;39(1):59-65
    Background: The prevalence of immunoglobulin E (IgE) mediated beef allergy in childhood is unknown. We investigated the prevalence and characteristics of IgE-mediated beef allergy in urban schoolchildren.

    Methods: This cross-sectional study recruited 6000 randomly selected urban schoolchildren ages 6-17 years from the city center of Giresun in the eastern Black Sea region of Turkey during 2013. Read More

    Heterogeneity of asthma and the risk of celiac disease in children.
    Allergy Asthma Proc 2018 Jan;39(1):51-58
    Background: Although human leukocyte antigen (HLA)-DR and HLA-DQ genes and gluten play crucial roles in developing celiac disease (CD), most patients with these risk factors still do not develop CD, which indicates additional unrecognized risk factors.

    Objective: To determine the association between asthma and the risk of CD in children.

    Methods: We conducted a population-based retrospective case-control study in children who resided in Olmsted County, Minnesota. Read More

    Systemic inflammation mediates the detrimental effects of obesity on asthma control.
    Allergy Asthma Proc 2018 Jan;39(1):43-50
    Background: Obesity negatively impacts asthma control, but the inflammatory mechanisms are poorly understood.

    Objective: To explore which systemic inflammatory mediators mediate the effects of obesity on asthma control.

    Methods: The subjects with stable asthma (n = 108) underwent assessment of clinical characteristics, which included using The Asthma Control Questionnaire (ACQ)-6. Read More

    The effect of omalizumab treatment on the low affinity immunoglobulin E receptor (CD23/fc epsilon RII) in patients with severe allergic asthma.
    Allergy Asthma Proc 2018 Jan;39(1):36-42
    Background: Omalizumab is an anti-immunoglobulin E (IgE) monoclonal antibody used in the treatment of severe asthma. Its therapeutic efficacy is primarily attributed to reduction of serum-free IgE and in the expression of high-affinity IgE receptor, fc epsilon RI. However, its effect on the low-affinity IgE receptor fc epsilon RII/CD23 in vivo has not been evaluated. Read More

    Characterizing patients with asthma who received Global Initiative for Asthma steps 4-5 therapy and managed in a specialty care setting.
    Allergy Asthma Proc 2018 Jan;39(1):27-35
    Background: Severe asthma is recognized in the European Respiratory Society/American Thoracic Society guidelines as a major unmet need in the management of asthma.

    Objective: The study objective was to describe the clinical burden of Global Initiative for Asthma (GINA) steps 4-5 asthma for patients treated by specialists in the U.S. Read More

    A review of the efficacy and safety of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with asthma.
    Allergy Asthma Proc 2018 Jan;39(1):14-26
    Background: Despite current guidelines, many patients with asthma remain symptomatic, particularly those intolerant of, unresponsive to, or uncontrolled by long-acting beta 2-agonists (LABAs). Tiotropium bromide, delivered through the Respimat soft-mist inhaler in 2 puffs of 1.25 micrograms each, is approved for the long-term, maintenance treatment of asthma in patients aged ≥6 years. Read More

    Chronic rhinosinusitis with nasal polyps in the elderly: Assessing current evidence.
    Allergy Asthma Proc 2018 Jan;39(1):9-13
    Background: The recently reported prevalence of chronic rhinosinusitis (CRS) among people >60 years old was 4.7%, with CRS emerging as the sixth most common chronic condition in the elderly. There is still a dearth of studies that focused on older patients, however, regarding the characteristics of CRS with nasal polyps (CRSwNP). Read More

    The dilemma of allergy to food additives.
    Allergy Asthma Proc 2018 Jan;39(1):3-8
    Objective: To provide a brief summary on food additives and to outline a practical approach for evaluating subjects suspected of having reactions to food additives.

    Data Sources: Information was derived from selected reviews and original articles published in peer-reviewed journals, supplemented by the clinical experience of the authors.

    Study Selection: Priority was given to studies that used blinded, placebo controlled, oral challenges to confirm adverse reactions to food additives. Read More

    Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.
    Allergy Asthma Proc 2018 Mar 5;39(2):127-135. Epub 2017 Dec 5.
    Allergy Partners P.A., Asheville, North Carolina.
    Background: Omalizumab is approved in patients with moderate-to-severe allergic asthma with symptoms uncontrolled, despite the mainstay therapy.

    Objective: Electronic medical records (EMR) were used to increase the knowledge of omalizumab effectiveness in a real-world setting.

    Methods: Patients with uncontrolled moderate-to-severe allergic asthma, ages ≥12 years old, initiated on omalizumab (index date), with ≥12 months of pre- and postindex data, were identified in an EMR data base. Read More

    Guidance for compassionate restraint of small children to prevent injuries with epinephrine autoinjectors.
    Allergy Asthma Proc 2018 Mar 29;39(2):161-165. Epub 2017 Nov 29.
    Background: Without securing a child properly, injuries can happen with the use of pediatric epinephrine autoinjectors (EAI), and lacerations and embedded needles have been reported. Health care providers should ensure that instruction is provided to parents on how to hold a child during an injection with an EAI.

    Objective: To demonstrate the compassionate restraint of small children during an allergic emergency to ensure the safe use of an EAI. Read More

    The age-related characteristics of adults with asthma who visited emergency departments in Korea from 2007 to 2012.
    Allergy Asthma Proc 2018 Mar 28;39(2):136-142. Epub 2017 Nov 28.
    Department of Pediatrics, Chungnam National University School of Medicine, Daejeon, Korea.
    Background: Understanding the patterns of emergency department (ED) visits of patients with asthma is important for disease control and prevention of exacerbations.

    Objective: This study aimed to investigate the characteristics of adult patients who visited EDs because of their asthma.

    Methods: Patients with asthma, ages ≥19 years old, who visited 117 EDs throughout Korea between January 2007 and December 2012 were identified in the National Emergency Department Information System (NEDIS) data base using the International Classification of Disease, 10th revision, codes J45 (asthma) and J46 (status asthmaticus). Read More

    A review of the efficacy and safety of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with asthma.
    Allergy Asthma Proc 2017 Nov 6. Epub 2017 Nov 6.
    Background: Despite current guidelines, many patients with asthma remain symptomatic, particularly those intolerant of,unresponsive to, or uncontrolled by long-acting beta 2-agonists (LABAs). Tiotropium bromide, delivered through the Respimatsoft-mist inhaler in 2 puffs of 1.25 micrograms each, is approved for the long-term, maintenance treatment of asthma in patients aged greater than or equal to 6 years. Read More

    The role of intravenous access during oral food challenges in food protein-induced enterocolitis syndrome.
    Allergy Asthma Proc 2017 Nov;38(6):467-473
    Background: Food protein-induced enterocolitis syndrome (FPIES) is a non-immunoglobulin E mediated food hypersensitivity syndrome characterized by profuse vomiting and diarrhea, which leads to lethargy, dehydration, and hypotension. Given the potential severity of reactions, resolution of FPIES is confirmed via oral food challenge (OFC) during which intravenous (IV) access is recommended to facilitate IV fluids (IVF) and steroid therapy. Risk factors for IV treatment are not well characterized. Read More

    Health-related quality of life in Danish children with hereditary angioedema.
    Allergy Asthma Proc 2017 Nov;38(6):440-446
    Background: The potentially life-threatening disease hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) can have considerable impact on the health-related quality of life (HRQoL) in adult patients. Half the patients with C1-INH-HAE develop symptoms before the age of 10 years. However, the HRQoL in children with C1-INH-HAE is almost unexplored. Read More

    Management of adverse reactions to biologic agents.
    Allergy Asthma Proc 2017 Nov;38(6):409-418
    Hypersensitivity reactions (HSR) to targeted biologic agents present as immediate reactions during infusion or as delayed reactions (after one or more exposures). The new classification includes phenotypes, endotypes, and biomarkers. Phenotypes include immediate type I (immunoglobulin E [IgE] or non-IgE mediated), cytokine release, mixed (type I/cytokine), and immune complexes type III (IgG mediated) reactions as well as delayed type IV reactions. Read More

    Interleukin 31 and skin diseases: A systematic review.
    Allergy Asthma Proc 2017 Nov;38(6):401-408
    Background: Although the pathophysiology of pruritus has been extensively studied in recent years, with many resultant advancements, management of pruritus is still enigmatic, particularly in chronic cutaneous diseases, such as atopic dermatitis, chronic urticaria, allergic contact dermatitis, cutaneous T-cell lymphoma, and uremic pruritus. The recent finding of the involvement of interleukin (IL) 31 in the pathogenesis of chronic pruritus has provided a novel approach to the management of chronic inflammatory skin disorders. The present report provided an in-depth overview of the role of IL-31 in chronic skin diseases and the possible diagnostic and therapeutic applications in the management of these diseases. Read More

    1 OF 41